US OptionsDetailed Quotes
MNMD240816P8000
- 0.55
- 0.000.00%
15min DelayTrading Jul 22 15:30 ET
0.00High0.00Low
0.00Open0.55Pre Close0 Volume554 Open Interest8.00Strike Price0.00Turnover91.92%IV12.35%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type-0.3245Delta0.1747Gamma15.45Leverage Ratio-0.0148Theta-0.0020Rho-5.01Eff Leverage0.0081Vega
Mind Medicine Stock Discussion
Sign in to post a comment
$Mind Medicine(MNMD.US$
A small position however, it isn't showing up on the ticker at all!
A small position however, it isn't showing up on the ticker at all!
3
$Mind Medicine(MNMD.US$ Reuters· 3 mins ago
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
$Mind Medicine(MNMD.US$
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
$Mind Medicine(MNMD.US$ MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
4
$Seelos Therapeutics(SEEL.US$ $Cybin(CYBN.US$ $Mind Medicine(MNMD.US$ FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
5
13
$Mind Medicine(MNMD.US$ i swear my brokerage (not moomoo) knows what stocks i buy and instantly shorts my stock
1
2
$Mind Medicine (MNMD.US)$ all work force buisness owner operators should invest into this companies products. this could not only benifit people with the disorders outlined in their descriptions but think about our work force in general I know for the agency I work for we have call ins all the time and generally speaking it's almost always the same people it isn't just my agency but national, jobs every wherewould benifit. so this company could help everyone every where! This company will ris...
1
$Mind Medicine(MNMD.US$ Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
1
1
No comment yet
IDKWTFIMDOINGOP : Still not showing. Kind of *ucked up if you ask me. Place an order for the ask and it never gets put on the ticker. Only low price orders are allowed to go through to drive down the price.
Manipulation!
IDKWTFIMDOINGOP : Still not on the ticker.....
IDKWTFIMDOINGOP : 1.5 hours later...still not on ticker.